The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Timofeeva A.A.

Device-aided therapies in advanced Parkinson’s disease

Authors:

Timofeeva A.A.

More about the authors

Read: 4360 times


To cite this article:

Timofeeva AA. Device-aided therapies in advanced Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2016;116(12):54‑60. (In Russ.)
https://doi.org/10.17116/jnevro201611612154-60

Recommended articles:
Diagnosis and treatment approaches for sialorrhea in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(10):29-34
Neurochemical mechanisms of tremor in Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):64-72
Cognitive impairment in patients with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):81-90
Bladder dysfunction in patients with stages I—III of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(11):91-99
A portrait of a doctor with Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2024;(12):160-164
Pathomorphosis of the Parkinson’s disease against the background of DBS STN. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(2):21-27
Neuroinflammatory and neurodegenerative aspe­cts of Parkinson’s disease. S.S. Korsakov Journal of Neurology and Psychiatry. 2025;(3):102-111

References:

  1. Levin OS, Fedorova NV. Parkinsons disease. M.: MEDpress-inform; 2014. (In Russ.).
  2. Shtok VN, Ivanova-Smolenskaja IA, Levin OS. Extrapyramidal disorders. M.: MEDpress-inform; 2002. (In Russ.).
  3. Wolters E, Baumann C. (Ed.) Parkinson disease and Other Movement Disorders. VU University Press; 2014.
  4. Jankovic J, Tolosa E. (Ed.) Parkinson’s disease and movement disorders. Philadelphia: Lippincott Williams & Wilkins; 2007.
  5. Levin OS. Levodopa and levodopaphobia. Nevrologicheskij zhurnal. 2010;4:4-11. (In Russ.).
  6. Palhagen S, Sydow O, Johansson A, Nyholm D, Holmberg B, Widner H, Dizdar N, Linder J, Hauge T, Jansson R, Bergmann L, Kjellander S, Marshall T. Levodopa-carbidopa intestinal gel (LCIG) treatment in routine care of patients with advanced Parkinsons disease: An open-label prospective observational study of effectiveness, tolerability and healthcare costs. Parkinsonism and Related disorders. 2016. doi: 10.1016/j.parkreldis.2016.06.002
  7. Volkmann J, Albanese A, Antonini A, Chaudhuri KR, Clarke CE, Rob MA de Bie, Deuscl G, Eggert K, Houeto JL, Kulisevsky J, Nyholm D, Odin P, Ostergaard K, Poewe W, Pollak P, Rabey JM, Rascol O, Ruzichka E, Samuel M, Speelman H, Sydow O, Valldeoriola F, Linden C, Oertel W. Selecting deep brainstimulation or infusion therapies in advanced Parkinsons disease: an evidence-based review. J Neurology. 2013;260:2701-2714. doi: 10.1007/s00415-012-6798-6
  8. Antonini A, Odin P, Kleinman L, Skalicky A, Marshall M, Sail K, Onuk K. Implementing a Delphi Panel to Improve Understanding of Patient Characteristics of Advanced Parkinson’s Disease. Presented at the 19th International Congress of Parkinson’s Disease and Movement Disorders, San Diego, California, United States, June 14—18, 2015.
  9. Odin P, Chaudhuri KR, Slevin JT, Volkmann J, Dietrichs E, Martinez-Martin P, Krauss JK, Henriksen T, Katzenschlager R, Antonini A, Rascol O, Poewe W. Collective physician perspectives on non-oral medication approaches for the management of clinically relevant unresolved issues in Parkinsons disease: Consensus from an international survey and discussion program. doi: 10.1016/j/ parkreldis.2015.07.020
  10. Antonini A, Fung VSC, Boid JT, Slevin JT, Hall C, Eaton S, Shatarma K, Benesh JA. Effect of Levodopa-Carbidopa Intestinal Gel on Dyskinesia in Advanced Parkinsons Disease Patients. Movements Disorders. 2016;31(4):530-537. doi: 10/1002/mds.26528
  11. Fernandes HH, Robieson WZ, Chatamra K, Dubow J, Eaton S, Benesh JA, Odin P. Effect of levodopa-carbidopa intestinal gel on resting tremor in patients with advanced Parkinsons disease. J Parkinsons Disease. 2016;2:16015. doi: 10.1038/npjparkd.2016.15
  12. Okun MS, Fernandez HH, Wu SS, Kirch-Darrow L, Bowers D, Bova F. Cognition and mood in Parkinson disease in subthalamic nucleus versus globus pallidus interna deep brain stimulation: the compare trial. Annals of neurology. 2009;65:586-595. doi: 10.1002/ana.21596
  13. Odekerken VJ, Laar T, Staal MJ, Mosch A, Hoffman CF, Nijssen PC. Subthalamic nucleus versus globus pallidus bilateralinterna deep brain stimulation for advanced Parkinson Disease (NSTAPS study): a randomized control trial. Lancet neurology. 2013;12:37-44. doi: 10.1016/S1474-4422(12)70264-8
  14. Martinez-Martin P, Reddy P, Katzenschlager R, Antonini A, Todorova A, Odin P. Eurolnf multicenter observational study of apomorfine and levodopa infusion in Parkinsons disease. Movements disorders. 2015;30:510-516. doi: 10.1002/mds.26067
  15. Garcia Ruiz PJ, Sesar Ignacio A, Pensado BA, Garcia AC, Alonso Frech F, Alvarez Lopez M et al. Efficacy of long-term continuous subcutaneous apomorphine infusion in advanced Parkinson's disease with motor fluctuations: a multicenter study. Movement Disorders. 2008;23:1130-1136.
  16. St George RJ, Nutt JG, Burchiel KJ, Horak FB. A meta-regression of the longterm effects of deep brain stimulation on balance and gait in PD. Neurology. 2010;75(14):1292-1299. doi: 10.1212/WNL.0b013e3181f61329
  17. Devos D, French DSG. Patient profile, indications, efficacy and safety of duodenal levodopa infusion in advanced Parkinson's disease. Movement Disorders. 2009;24:24993-1000. doi: 10.1002/mds.22450
  18. Russmann H, Ghika J, Villemure JG, Robert B, Bogousslavsky J, Burkhard PR et al. Subthalamic nucleus deep brain stimulation in Parkinson disease patients over age 70 years. Neurology. 2004;63:1952-1954.
  19. Antonini A, Albin RL. Dopaminergic treatment and nonmotor features of Parkinson disease: the horse lives. Neurology. 2013;80:784-785.
  20. Reddy P, Martinez-Martin P, Antonini A, Calandrella D, Pilleri M, Odin P et al. A multicentre European comparative survey of motor and non-motor effects of subcutaneous apomorphine infusion and intrajejunal levodopa infusion in Parkinson's disease. Movement Disorders. 2012;27:49. doi: 10.1002/mds.25053
  21. Martinez-Martin P, Reddy P, Antonini A, Henriksen T, Katzenschlager R, Odin P et al. Chronic subcutaneous infusion therapy with apomorphine in advanced Parkinson's disease compared to conventional therapy: a real life study of non-motor effect. J of Parkinsons Disease. 2011;1:197-203.
  22. Eggert K, Schrader C, Hahn M, Stamelou M, Russmann A, Dengler R et al. Continuous jejunal levodopa infusion in patients with advanced parkinson disease: practical aspects and outcome of motor and non-motor complications. Clinical Neuropharmacoljgy. 2008;31:151-166. doi: 10.197/wnf.0b013e31814b113e
  23. Honig H, Antonini A, Martinez-Martin P, Forgacs I, Faye GC, Fox T, Fox K, Mancini F, Canesi M, Odin P, Chaudhuri KR. Intrajejunal levodopa infusion in Parkinson's disease: a pilot multicenter study of effects on nonmotor symptoms and quality of life. Movement Disorders. 2009;24:1468-1474. doi: 10.1002/mds.22596

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.